<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03836066</url>
  </required_header>
  <id_info>
    <org_study_id>GECP 18/03_TELMA</org_study_id>
    <nct_id>NCT03836066</nct_id>
  </id_info>
  <brief_title>Atezolizumab Plus Bevacizumab in First Line NSCLC Patients</brief_title>
  <acronym>TELMA</acronym>
  <official_title>A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer (NSCLC) Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación GECP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación GECP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center phase II clinical trial of atezolizumab in combination with&#xD;
      bevacizumab as first line treatment for locally advanced or metastasic high-intermediate&#xD;
      tumour mutation burden selected NSCLC patients. 102 patients will be enrolled in this trial&#xD;
      to examine the efficacy of this combination measured by progression free survival according&#xD;
      to response evaluation Criteria in solid tumours (RECIST) version 1.1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy-naïve patients high-intermediate TMB (TMB≥10 mutations/MB) and with locally&#xD;
      advanced or metastatic non-squamous non-small cell lung cancer patients will be selected.&#xD;
      Enroled patientswill receive 1200 mg of atezolizumab and 15mg/Kg of Avastin® (bevacizumab)&#xD;
      administered by IV infusion every 21 days (+/- 3 days).&#xD;
&#xD;
      The treatment will start within 1-5 days from enrolment. Atezolizumab may continue beyond&#xD;
      disease progression per RECIST v1.1 until loss of clinical benefit, unacceptable toxicity,&#xD;
      patient or physician decision to discontinue , or death. Bevacizumab will be administered&#xD;
      until progression disease, unacceptable toxicity, patient or physician decision to&#xD;
      discontinue or death.&#xD;
&#xD;
      For all patients, tumour response data collection will continue until disease progression,&#xD;
      even if the patient stops study treatment prior to disease progression.&#xD;
&#xD;
      The primary endpoint is to evaluate the efficacy of Atezolizumab in combination with&#xD;
      Bevacizumab as measured by Progression Free Survival according to RECIST Version 1.1.&#xD;
&#xD;
      PFS after enrolment is defined as the time from enrolment to the first occurrence of disease&#xD;
      progression or death from any cause, whichever occurs first.&#xD;
&#xD;
      Patient accrual is expected to be completed within 1.5 years excluding a run-in-period of 46&#xD;
      months. Treatment and follow-up are expected to extend the study duration to a total of 4.5&#xD;
      years. Patients will be followed 1.5 years after the end of treatment independently of the&#xD;
      cause of end of treatment. The study will end once survival follow-up has concluded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Atezolizumab in combination with Bevacizumab</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</time_frame>
    <description>To evaluate the efficacy of Atezolizumab in combination with Bevacizumab as measured by Progression Free Survival according to Response Evaluation Criteria in Solid Tumours (RECIST).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental: Atezolizumab plus Bevacizumab arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 group, Atezolizumab 1200mb + Bevacizumab 15 mg/kg (IV),every 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab-Bevacizumab</intervention_name>
    <description>Atezoluzumab 1200 mg + Bevacizumab 15 mg / kg</description>
    <arm_group_label>Experimental: Atezolizumab plus Bevacizumab arm</arm_group_label>
    <other_name>Tecentriq-Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged ≥ 18 years old&#xD;
&#xD;
          2. ECOG performance status of 0 or 1.&#xD;
&#xD;
          3. Histologically or cytologically confirmed, Stage IIIB or IV non-squamous NSCLC&#xD;
             according to 8th version of the International Association for the Study of Lung Cancer&#xD;
             Staging Manual in Thoracic Oncology&#xD;
&#xD;
          4. No prior treatment for Stage IIIB or IV non-squamous NSCLC.&#xD;
&#xD;
          5. Patients who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or&#xD;
             chemo-radiotherapy with curative intent for non-metastatic disease must have&#xD;
             experienced a treatment-free interval of at least 6 months from randomization since&#xD;
             the last chemotherapy, radiotherapy, or chemo-radiotherapy.&#xD;
&#xD;
          6. Patients with a treated asymptomatic CNS metastasis are eligible, provided they meet&#xD;
             all of the following criteria:&#xD;
&#xD;
               1. Only supratentorial and cerebellar metastases allowed (i.e., no metastases to&#xD;
                  midbrain, pons, medulla or spinal cord).&#xD;
&#xD;
               2. No ongoing requirement for corticosteroids as therapy for CNS disease.&#xD;
&#xD;
               3. No stereotactic radiation within 7 days or whole-brain radiation within 14 days&#xD;
                  prior to randomization.&#xD;
&#xD;
               4. No evidence of interim progression between the completion of CNS-directed therapy&#xD;
                  and the screening radiographic study. Patients with new asymptomatic CNS&#xD;
                  metastases detected at the screening scan must receive radiation therapy and/or&#xD;
                  surgery for CNS metastases. Following treatment, these patients may then be&#xD;
                  eligible without the need for an additional brain scan prior to inclusion, if all&#xD;
                  other criteria are met.&#xD;
&#xD;
          7. Patients with high-intermediate Tumour Mutational Burden analysed by Foundation&#xD;
             Medicine (≥10 mutations/ MB) performed by a Foundation Medicine laboratory on&#xD;
             previously obtained archival tumour tissue or tissue obtained from a biopsy at&#xD;
             prescreening (sample must fulfil minimal sample requirements of 20% tumour cellularity&#xD;
             and a minimum surface of 25mm2).&#xD;
&#xD;
          8. Measurable disease, as defined by RECIST v1.1. Previously irradiated lesions can only&#xD;
             be considered as measurable disease if disease progression has been unequivocally&#xD;
             documented at that site since radiation and the previously irradiated lesion is not&#xD;
             the only site of disease.&#xD;
&#xD;
          9. Adequate hematologic and organ function defined by the following laboratory results&#xD;
             obtained within 14 days prior to randomization:&#xD;
&#xD;
             Neutrophils ≥ 1500 cells/μL without granulocyte colony-stimulating factor support.&#xD;
&#xD;
               -  Lymphocyte count ≥ 500/μL.&#xD;
&#xD;
               -  Platelet count ≥ 100,000/μL without transfusion.&#xD;
&#xD;
               -  Haemoglobin ≥ 9.0 g/dL. Patients may be transfused to meet this criterion.&#xD;
&#xD;
               -  INR or aPTT ≤ 1.5 × upper limit of normal (ULN). This applies only to patients&#xD;
                  who are not receiving therapeutic anticoagulation; patients receiving therapeutic&#xD;
                  anticoagulation should be on a stable dose.&#xD;
&#xD;
               -  AST, ALT, and alkaline phosphatase ≤ 2.5 × ULN, with the following exceptions:&#xD;
                  Patients with documented liver metastases: AST and/or ALT ≤ 5 × ULN. Patients&#xD;
                  with documented liver or bone metastases: alkaline phosphatase ≤ 5 × ULN.&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.25 × ULN. Patients with known Gilbert disease who have serum&#xD;
                  bilirubin level ≤ 3 × ULN may be enrolled.&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 × ULN or creatinine clearance of ≥45ml/min (based on the&#xD;
                  Cockcroft Gault formula).&#xD;
&#xD;
         10. All patients are notified of the investigational nature of this study and signed a&#xD;
             written informed consent in accordance with institutional and national guidelines,&#xD;
             including the Declaration of Helsinki prior to any trial-related intervention.&#xD;
&#xD;
         11. For female patients of childbearing potential, agreement (by patient and/or partner)&#xD;
             to use a highly effective form(s) of contraception that results in a low failure rate&#xD;
             (&lt; 1% per year) when used consistently and correctly, and to continue its use for 5&#xD;
             months after the last dose of Atezolizumab and/or 6 months after the last dose of&#xD;
             Bevacizumab, whichever is later. Such methods include: combined (oestrogen and&#xD;
             progestogen containing) hormonal contraception, progestogen-only hormonal&#xD;
             contraception associated with inhibition of ovulation together with another additional&#xD;
             barrier method always containing a spermicide, intrauterine device (IUD): intrauterine&#xD;
             hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner (on&#xD;
             the understanding that this is the only one partner during the whole study duration),&#xD;
             and sexual abstinence.&#xD;
&#xD;
         12. For male patients with female partners of childbearing potential, agreement (by&#xD;
             patient and/or partner) to use a highly effective form(s) of contraception that&#xD;
             results in a low failure rate [&lt; 1% per year] when used consistently and correctly,&#xD;
             and to continue its use for 6 months after the last dose of Bevacizumab. Male patients&#xD;
             should not donate sperm during this study and for at least 6 months after the last&#xD;
             dose of Bevacizumab.&#xD;
&#xD;
         13. Oral contraception should always be combined with an additional contraceptive method&#xD;
             because of a potential interaction with the study drugs. The same rules are valid for&#xD;
             male patients involved in this clinical study if they have a partner of childbirth&#xD;
             potential. Male patients must always use a condom.&#xD;
&#xD;
         14. Women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or&#xD;
             surgically sterile must have a negative serum pregnancy test result within 14 days&#xD;
             prior to initiation of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a sensitizing mutation in the epidermal growth factor receptor (EGFR)&#xD;
             gene.&#xD;
&#xD;
          2. Patients with an anaplastic lymphoma kinase (ALK) fusion oncogene.&#xD;
&#xD;
          3. Patients with an STK-1 Ligand alteration.&#xD;
&#xD;
          4. Patients with MDM2 amplification.&#xD;
&#xD;
          5. Patients with ROS1 translocations.&#xD;
&#xD;
          6. Active or untreated CNS metastases as determined by CT or magnetic resonance imaging&#xD;
             (MRI) evaluation during screening and prior radiographic assessments.&#xD;
&#xD;
          7. Spinal cord compression not definitively treated with surgery and/or radiation or&#xD;
             previously diagnosed and treated spinal cord compression without evidence that disease&#xD;
             has been clinically stable for &gt; 2 weeks prior to randomization.&#xD;
&#xD;
          8. Leptomeningeal disease.&#xD;
&#xD;
          9. Uncontrolled tumour-related pain. Patients requiring pain medication must be on a&#xD;
             stable regimen at study entry. Symptomatic lesions amenable to palliative radiotherapy&#xD;
             (e.g., bone metastases or metastases causing nerve impingement) should be treated&#xD;
             prior to initiation of study drug. Patients should be recovered from the effects of&#xD;
             radiation. There is no required minimum recovery period. Asymptomatic metastatic&#xD;
             lesions whose further growth would likely cause functional deficits or intractable&#xD;
             pain (e.g., epidural metastasis that is not currently associated with spinal cord&#xD;
             compression) should be considered for locoregional therapy, if appropriate, prior to&#xD;
             initiation of study drug.&#xD;
&#xD;
         10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures (once monthly or more frequently). Patients with indwelling&#xD;
             catheters (e.g., PleurX®) are allowed.&#xD;
&#xD;
         11. Uncontrolled or symptomatic hypercalcemia (&gt; 1.5 mmol/L ionized calcium or Ca &gt; 12&#xD;
             mg/dL or corrected serum calcium &gt; ULN).&#xD;
&#xD;
         12. Malignancies other than NSCLC within 5 years prior to randomization, with the&#xD;
             exception of those with a negligible risk of metastasis or death (e.g., expected&#xD;
             5-year OS &gt; 90%) treated with expected curative outcome (such as adequately treated&#xD;
             carcinoma in situ of the cervix, basal or squamous-cell skin cancer, localized&#xD;
             prostate cancer treated surgically with curative intent, ductal carcinoma in situ&#xD;
             treated surgically with curative intent).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariano Provencio, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta de Hierro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <state>La Coruña</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Mallorca</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Llàtzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Mallorca</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospitalario Provincial de Castelló</name>
      <address>
        <city>Castelló</city>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Toledo</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politécnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gecp.org</url>
    <description>Web page of the sponsor where users can find more information about Fundación GECP studies</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC, Atezolizumab, Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

